What SEC filings does aTyr Pharma, Inc. submit to the SEC?

aTyr Pharma, Inc. (ATYR) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ATYR?

A Form 4 for ATYR discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from aTyr Pharma, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ATYR?

The 10-K is aTyr Pharma, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ATYR SEC filings directly on EDGAR?

You can view all historical aTyr Pharma, Inc. filings on the SEC EDGAR company page for ATYR. Each filing card on this page links directly to the original SEC document.

How often does aTyr Pharma, Inc. file with the SEC?

aTyr Pharma, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ATYR shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ATYR SEC Filing News — aTyr Pharma, Inc.

Latest SEC filings for aTyr Pharma, Inc. (ATYR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-01.

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment …

Sector: Healthcare Industry: Biotechnology Market Cap: $16.6M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ATYR currently lean bullish. Of the 12 displayed SEC filing records, 1 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 4 insider transactions (Form 4) in this period.

ATYR Filing Activity Snapshot 2026-05-13 — 2026-10-01

Insider Transactions (Form 4)

1 buy vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$49.6K

SCHIMMEL PAUL (Director) · 2026-05-28

100,000 shares · Form 4

Insider Transactions 4 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 4 filings in this group are Form 4s for aTyr Pharma, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 4 insider filings shown, the breakdown is 3 compensation award and 1 open-market purchase. 1 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×3: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-10-01

ATYR insider Form 4 filed for equity award, exercise, or tax withholding

Yaras Brandon (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	410,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Yaras Brandon (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-28

ATYR insider SCHIMMEL PAUL (Director) bought 100,000 shares (~$49.6K)

SCHIMMEL PAUL, listed as Director at aTYR PHARMA INC, reported an open-market purchase of 100,000 ATYR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$0.50	$49.6K

Filing: Form 4 (Insider Transaction) Insider: SCHIMMEL PAUL (Director) Shares: 100,000 Est. Value: $49.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-13

ATYR insider Form 4 filed for equity award, exercise, or tax withholding

Coughlin Timothy (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	50,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Coughlin Timothy (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-13

ATYR insider Form 4 filed for equity award, exercise, or tax withholding

BENEVICH ERIC (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	50,000	—	—

Filing: Form 4 (Insider Transaction) Insider: BENEVICH ERIC (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for aTyr Pharma, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-24